Maynard Um
-
-
-
-
-
-
-
BridgeBio shares new acoramidis data showing cardiovascular benefits
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
William Blair: 'we view BridgeBio as a core smidcap biotech holding'
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) Gains Tied to Market Chatter
-
-
-
-
-
-
-
Morgan Stanley Starts BridgeBio Pharma (BBIO) at Overweight
-
404,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

